Sanuwave Health, Inc. (SNWV) provided a preliminary revenue update for the second quarter of 2026, reflecting a year-over-year revenue decline. However, the expected revenue exceeds the company's revised guidance issued on June 16, 2026. Sanuwave Health focuses on patented, non-invasive directed-energy...
Shares of SANUWAVE Health, Inc. (SNWV) tumbled 40% on Tuesday morning after the company lowered its second-quarter revenue outlook, citing weakness in capital equipment sales for its Ultramist wound care system. The stock is currently trading at $8.75, down $5.92 or 40.35%, on the Nasdaq. It opened...
Sanuwave Health, Inc.(SNWV), a medical devices company, said on Friday that it expects its fourth-quarter revenue to be in the range of $13.3 million to $13.4 million, an increase of 29% to 30% from the same period last year. Morgan Frank, CEO of Sanuwave Health, said: "As we discussed when releasing...
SANUWAVE Health Inc. (SNWV.OB) revealed earnings for second quarter that Drops, from last year The company's earnings came in at $1.05 million, or $0.01 per share. This compares with $6.56 million, or $1.77 per share, last year. The company's revenue for the period rose 41.9% to $10.16 million...
SANUWAVE Health Inc. (SNWV), a provider of next-generation FDA-approved wound care products, is slated to release its full Q1 results on or around May 9, 2025.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.